targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000065518 | MONDO_0005148 | NCT00261352 | Terminated | 3 | 2005-03-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,125,281,431,646 | The development program has been terminated | Phase 3 | 31/03/2005 | Terminated | 22/04/2009 | 31/12/2006 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00261352 | Terminated | 3 | 2005-03-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,125,281,431,646 | The development program has been terminated | Phase 3 | 31/03/2005 | Terminated | 22/04/2009 | 31/12/2006 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00261352 | Terminated | 3 | 2005-03-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,125,281,431,646 | The development program has been terminated | Phase 3 | 31/03/2005 | Terminated | 22/04/2009 | 31/12/2006 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00598793 | Completed | 3 | 2002-11-01 | null | null | null | Phase III+ | Phase II+ | 1,125,281,432,345 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00598793 | Completed | 3 | 2002-11-01 | null | null | null | Phase III+ | Phase II+ | 1,125,281,432,345 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00598793 | Completed | 3 | 2002-11-01 | null | null | null | Phase III+ | Phase II+ | 1,125,281,432,345 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02099110 | Completed | 3 | 2014-04-22 | null | null | null | Phase III+ | Phase II+ | 1,133,871,367,055 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02099110 | Completed | 3 | 2014-04-22 | null | null | null | Phase III+ | Phase II+ | 1,133,871,367,055 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02099110 | Completed | 3 | 2014-04-22 | null | null | null | Phase III+ | Phase II+ | 1,133,871,367,055 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02831361 | Completed | 3 | 2016-10-17 | null | null | null | Phase III+ | Phase II+ | 1,133,871,367,658 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02831361 | Completed | 3 | 2016-10-17 | null | null | null | Phase III+ | Phase II+ | 1,133,871,367,658 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02831361 | Completed | 3 | 2016-10-17 | null | null | null | Phase III+ | Phase II+ | 1,133,871,367,658 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01340664 | Completed | 2 | 2011-07-01 | null | null | null | null | Phase II+ | 1,133,871,367,915 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01340664 | Completed | 2 | 2011-07-01 | null | null | null | null | Phase II+ | 1,133,871,367,915 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01340664 | Completed | 2 | 2011-07-01 | null | null | null | null | Phase II+ | 1,133,871,367,915 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04667143 | Not yet recruiting | 3 | 2021-01-01 | null | null | null | Phase III+ | Phase II+ | 1,133,871,368,002 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04667143 | Not yet recruiting | 3 | 2021-01-01 | null | null | null | Phase III+ | Phase II+ | 1,133,871,368,002 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04667143 | Not yet recruiting | 3 | 2021-01-01 | null | null | null | Phase III+ | Phase II+ | 1,133,871,368,002 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01368081 | Completed | 3 | 2011-05-01 | null | null | null | Phase III+ | Phase II+ | 1,168,231,104,946 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01368081 | Completed | 3 | 2011-05-01 | null | null | null | Phase III+ | Phase II+ | 1,168,231,104,946 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01368081 | Completed | 3 | 2011-05-01 | null | null | null | Phase III+ | Phase II+ | 1,168,231,104,946 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04065581 | Completed | 1 | 2019-10-14 | null | null | null | null | null | 1,168,231,105,104 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04065581 | Completed | 1 | 2019-10-14 | null | null | null | null | null | 1,168,231,105,104 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04065581 | Completed | 1 | 2019-10-14 | null | null | null | null | null | 1,168,231,105,104 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04807348 | Recruiting | 3 | 2021-05-17 | null | null | null | Phase III+ | Phase II+ | 1,168,231,105,173 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04807348 | Recruiting | 3 | 2021-05-17 | null | null | null | Phase III+ | Phase II+ | 1,168,231,105,173 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04807348 | Recruiting | 3 | 2021-05-17 | null | null | null | Phase III+ | Phase II+ | 1,168,231,105,173 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01006590 | Completed | 4 | 2009-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,168,231,105,866 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01006590 | Completed | 4 | 2009-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,168,231,105,866 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01006590 | Completed | 4 | 2009-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,168,231,105,866 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00525330 | Completed | 2 | 2007-09-01 | null | null | null | null | Phase II+ | 1,168,231,106,051 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00525330 | Completed | 2 | 2007-09-01 | null | null | null | null | Phase II+ | 1,168,231,106,051 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00525330 | Completed | 2 | 2007-09-01 | null | null | null | null | Phase II+ | 1,168,231,106,051 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00789035 | Completed | 2 | 2008-10-01 | null | null | null | null | Phase II+ | 1,219,770,712,157 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00789035 | Completed | 2 | 2008-10-01 | null | null | null | null | Phase II+ | 1,219,770,712,157 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00789035 | Completed | 2 | 2008-10-01 | null | null | null | null | Phase II+ | 1,219,770,712,157 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00830076 | Completed | 1 | 2008-12-02 | null | null | null | null | null | 1,219,770,712,238 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00830076 | Completed | 1 | 2008-12-02 | null | null | null | null | null | 1,219,770,712,238 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00830076 | Completed | 1 | 2008-12-02 | null | null | null | null | null | 1,219,770,712,238 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03751657 | Completed | 2 | 2018-11-29 | null | null | null | null | Phase II+ | 1,219,770,712,257 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03751657 | Completed | 2 | 2018-11-29 | null | null | null | null | Phase II+ | 1,219,770,712,257 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03751657 | Completed | 2 | 2018-11-29 | null | null | null | null | Phase II+ | 1,219,770,712,257 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01519674 | Completed | 4 | 2012-06-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,219,770,712,495 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01519674 | Completed | 4 | 2012-06-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,219,770,712,495 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01519674 | Completed | 4 | 2012-06-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,219,770,712,495 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00857870 | Completed | 4 | 2009-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,219,770,712,586 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00857870 | Completed | 4 | 2009-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,219,770,712,586 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00857870 | Completed | 4 | 2009-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,219,770,712,586 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00754689 | Withdrawn | 3 | 2008-09-01 | Withdrawn | stopped | null | Phase III+ | Phase II+ | 1,219,770,713,001 | Company decision taken in light of demands by certain national health authorities | Phase 3 | 30/09/2008 | Withdrawn | 17/05/2016 | 30/11/2008 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00754689 | Withdrawn | 3 | 2008-09-01 | Withdrawn | stopped | null | Phase III+ | Phase II+ | 1,219,770,713,001 | Company decision taken in light of demands by certain national health authorities | Phase 3 | 30/09/2008 | Withdrawn | 17/05/2016 | 30/11/2008 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00754689 | Withdrawn | 3 | 2008-09-01 | Withdrawn | stopped | null | Phase III+ | Phase II+ | 1,219,770,713,001 | Company decision taken in light of demands by certain national health authorities | Phase 3 | 30/09/2008 | Withdrawn | 17/05/2016 | 30/11/2008 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01941199 | Completed | 1 | 2013-07-01 | null | null | null | null | null | 1,219,770,714,080 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01941199 | Completed | 1 | 2013-07-01 | null | null | null | null | null | 1,219,770,714,080 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01941199 | Completed | 1 | 2013-07-01 | null | null | null | null | null | 1,219,770,714,080 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01966978 | Completed | 4 | 2014-11-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,228,360,646,933 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01966978 | Completed | 4 | 2014-11-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,228,360,646,933 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01966978 | Completed | 4 | 2014-11-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,228,360,646,933 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00532935 | Completed | 3 | 2008-01-26 | null | null | null | Phase III+ | Phase II+ | 1,228,360,647,053 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00532935 | Completed | 3 | 2008-01-26 | null | null | null | Phase III+ | Phase II+ | 1,228,360,647,053 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00532935 | Completed | 3 | 2008-01-26 | null | null | null | Phase III+ | Phase II+ | 1,228,360,647,053 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03761134 | Terminated | 3 | 2018-11-30 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,262,720,385,948 | Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies. | Phase 3 | 30/11/2018 | Terminated | 21/07/2020 | 29/04/2020 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03761134 | Terminated | 3 | 2018-11-30 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,262,720,385,948 | Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies. | Phase 3 | 30/11/2018 | Terminated | 21/07/2020 | 29/04/2020 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03761134 | Terminated | 3 | 2018-11-30 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,262,720,385,948 | Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies. | Phase 3 | 30/11/2018 | Terminated | 21/07/2020 | 29/04/2020 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01211197 | Completed | 1 | 2010-10-01 | null | null | null | null | null | 1,262,720,386,194 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01211197 | Completed | 1 | 2010-10-01 | null | null | null | null | null | 1,262,720,386,194 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01211197 | Completed | 1 | 2010-10-01 | null | null | null | null | null | 1,262,720,386,194 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00482729 | Completed | 3 | 2007-06-19 | null | null | null | Phase III+ | Phase II+ | 1,262,720,386,208 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00482729 | Completed | 3 | 2007-06-19 | null | null | null | Phase III+ | Phase II+ | 1,262,720,386,208 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00482729 | Completed | 3 | 2007-06-19 | null | null | null | Phase III+ | Phase II+ | 1,262,720,386,208 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01725672 | Terminated | 1 | 2012-09-27 | Terminated | stopped | null | null | null | 1,262,720,386,210 | Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines. | Phase 1 | 27/09/2012 | Terminated | 12/06/2017 | 21/08/2013 | Study_Design | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01725672 | Terminated | 1 | 2012-09-27 | Terminated | stopped | null | null | null | 1,262,720,386,210 | Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines. | Phase 1 | 27/09/2012 | Terminated | 12/06/2017 | 21/08/2013 | Study_Design | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01725672 | Terminated | 1 | 2012-09-27 | Terminated | stopped | null | null | null | 1,262,720,386,210 | Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines. | Phase 1 | 27/09/2012 | Terminated | 12/06/2017 | 21/08/2013 | Study_Design | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01725672 | Terminated | 1 | 2012-09-27 | Terminated | stopped | null | null | null | 1,262,720,386,210 | Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines. | Phase 1 | 27/09/2012 | Terminated | 12/06/2017 | 21/08/2013 | Regulatory | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01725672 | Terminated | 1 | 2012-09-27 | Terminated | stopped | null | null | null | 1,262,720,386,210 | Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines. | Phase 1 | 27/09/2012 | Terminated | 12/06/2017 | 21/08/2013 | Regulatory | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01725672 | Terminated | 1 | 2012-09-27 | Terminated | stopped | null | null | null | 1,262,720,386,210 | Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines. | Phase 1 | 27/09/2012 | Terminated | 12/06/2017 | 21/08/2013 | Regulatory | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00734474 | Completed | 2 | 2008-08-01 | null | null | null | null | Phase II+ | 1,262,720,386,380 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00734474 | Completed | 2 | 2008-08-01 | null | null | null | null | Phase II+ | 1,262,720,386,380 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00734474 | Completed | 2 | 2008-08-01 | null | null | null | null | Phase II+ | 1,262,720,386,380 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00118963 | Completed | 4 | 2003-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,271,310,320,333 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00118963 | Completed | 4 | 2003-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,271,310,320,333 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00118963 | Completed | 4 | 2003-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,271,310,320,333 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01059825 | Completed | 2 | 2010-02-24 | null | null | null | null | Phase II+ | 1,314,259,992,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01059825 | Completed | 2 | 2010-02-24 | null | null | null | null | Phase II+ | 1,314,259,992,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01059825 | Completed | 2 | 2010-02-24 | null | null | null | null | Phase II+ | 1,314,259,992,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00295633 | Completed | 3 | 2006-03-01 | null | null | null | Phase III+ | Phase II+ | 1,314,259,993,296 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00295633 | Completed | 3 | 2006-03-01 | null | null | null | Phase III+ | Phase II+ | 1,314,259,993,296 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00295633 | Completed | 3 | 2006-03-01 | null | null | null | Phase III+ | Phase II+ | 1,314,259,993,296 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00839527 | Completed | 3 | 2009-02-01 | null | null | null | Phase III+ | Phase II+ | 1,348,619,731,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00839527 | Completed | 3 | 2009-02-01 | null | null | null | Phase III+ | Phase II+ | 1,348,619,731,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00839527 | Completed | 3 | 2009-02-01 | null | null | null | Phase III+ | Phase II+ | 1,348,619,731,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05108350 | Not yet recruiting | 1 | 2021-11-09 | null | null | null | null | null | 1,348,619,731,693 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05108350 | Not yet recruiting | 1 | 2021-11-09 | null | null | null | null | null | 1,348,619,731,693 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT05108350 | Not yet recruiting | 1 | 2021-11-09 | null | null | null | null | null | 1,348,619,731,693 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01787396 | Completed | 3 | 2013-04-01 | null | null | null | Phase III+ | Phase II+ | 1,365,799,600,205 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01787396 | Completed | 3 | 2013-04-01 | null | null | null | Phase III+ | Phase II+ | 1,365,799,600,205 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01787396 | Completed | 3 | 2013-04-01 | null | null | null | Phase III+ | Phase II+ | 1,365,799,600,205 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01910441 | Terminated | 4 | 2013-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 1,365,799,600,473 | The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point. | Phase 4 | 31/07/2013 | Terminated | 28/10/2015 | 30/09/2014 | Logistics_Resources | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01910441 | Terminated | 4 | 2013-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 1,365,799,600,473 | The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point. | Phase 4 | 31/07/2013 | Terminated | 28/10/2015 | 30/09/2014 | Logistics_Resources | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01910441 | Terminated | 4 | 2013-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 1,365,799,600,473 | The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point. | Phase 4 | 31/07/2013 | Terminated | 28/10/2015 | 30/09/2014 | Logistics_Resources | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02411825 | Completed | 1 | 2015-03-01 | null | null | null | null | null | 1,365,799,600,650 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
Subsets and Splits